Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 5
2004 3
2005 3
2006 2
2007 3
2008 6
2009 6
2010 11
2011 10
2012 8
2013 14
2014 8
2015 8
2016 8
2017 15
2018 20
2019 23
2020 25
2021 19
2022 26
2023 25
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Results by year

Filters applied: . Clear all
Page 1
New insights into the treatment of obesity.
Blüher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, Pietiläinen KH, Schnell O, Tonchevska E, Wilding JPH. Blüher M, et al. Among authors: giorgino f. Diabetes Obes Metab. 2023 Aug;25(8):2058-2072. doi: 10.1111/dom.15077. Epub 2023 May 5. Diabetes Obes Metab. 2023. PMID: 37055715 Review.
SGLT-2 inhibitors as cardio-renal protective agents.
Caruso I, Giorgino F. Caruso I, et al. Among authors: giorgino f. Metabolism. 2022 Feb;127:154937. doi: 10.1016/j.metabol.2021.154937. Epub 2021 Nov 19. Metabolism. 2022. PMID: 34808144 Review.
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism.
Genchi VA, Rossi E, Lauriola C, D'Oria R, Palma G, Borrelli A, Caccioppoli C, Giorgino F, Cignarelli A. Genchi VA, et al. Among authors: giorgino f. Int J Mol Sci. 2022 Jul 25;23(15):8194. doi: 10.3390/ijms23158194. Int J Mol Sci. 2022. PMID: 35897769 Free PMC article. Review.
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Ludvik B, et al. Among authors: giorgino f. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Hernandez AF, et al. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2. Lancet. 2018. PMID: 30291013 Free article. Clinical Trial.
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.
Caruso I, Di Gioia L, Di Molfetta S, Cignarelli A, Palmer SC, Natale P, Strippoli GFM, Perrini S, Natalicchio A, Laviola L, Giorgino F. Caruso I, et al. Among authors: giorgino f. EClinicalMedicine. 2023 Sep 12;64:102181. doi: 10.1016/j.eclinm.2023.102181. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37719418 Free PMC article.
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators. Fioretto P, et al. Among authors: giorgino f. Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Diabetes Obes Metab. 2018. PMID: 29888547 Free PMC article. Clinical Trial.
239 results